التفاصيل البيبلوغرافية
| العنوان: |
1256TiP Phase III study of pembrolizumab (Pembro) with concurrent chemoradiation therapy (CCRT) followed by pembro with or without olaparib (Ola) vs CCRT followed by durvalumab (Durva) in unresectable, locally advanced, stage III non-small cell lung cancer (NSCLC): KEYLYNK-012 |
| المؤلفون: |
Jabbour, S., Cho, B.C., Bria, E., Kato, T., Bhosle, J., Gainor, J.F., Reguart, N., Wang, L., Morgensztern, D., Gurary, E.B., Ashraf, T.B., Lara-Guerra, H., Reck, M. |
| المصدر: |
In Annals of Oncology September 2020 31 Supplement 4:S810-S811 |
| قاعدة البيانات: |
ScienceDirect |
